Next Article in Journal
Centromeric Non-Coding RNAs: Conservation and Diversity in Function
Previous Article in Journal
MicroRNAs as Appropriate Discriminators in Non-Specific Alpha-Fetoprotein (AFP) Elevation in Testicular Germ Cell Tumor Patients
Previous Article in Special Issue
Long Non-Coding RNA in Vascular Disease and Aging
Open AccessCommentary

The Missing “lnc” between Genetics and Cardiac Disease

1
INRS Centre Armand-Frappier Santé Biotechnologie, Laval, QC H7V 1B7, Canada
2
Department of Genetics & Cell Biology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, PO box 616, 6200MD, Maastricht, the Netherlands
3
Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, PO Box 616, The Netherlands
4
Centre for Molecular and Vascular Biology (CMVB), Department of Cardiovascular Sciences, KU Leuven, B3000 Leuven, Belgium
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Non-Coding RNA 2020, 6(1), 3; https://doi.org/10.3390/ncrna6010003
Received: 13 December 2019 / Revised: 9 January 2020 / Accepted: 10 January 2020 / Published: 14 January 2020
(This article belongs to the Collection Regulatory RNAs in Cardiovascular Development and Disease)
: Cardiovascular disease (CVD) is one of the biggest threats to public health worldwide. Identifying key genetic contributors to CVD enables clinicians to assess the most effective treatment course and prognosis, as well as potentially inform family members. This often involves either whole exome sequencing (WES) or targeted panel analysis of known pathogenic genes. In the future, tailored or personalized therapeutic strategies may be implemented, such as gene therapy. With the recent revolution in deep sequencing technologies, we know that up to 90% of the human genome is transcribed, despite only 2% of the 6 billion DNA bases coding for proteins. The long non-coding RNA (lncRNA) “genes” make up an important and significant fraction of this “dark matter” of the genome. We highlight how, despite lncRNA genes exceeding that of classical protein-coding genes by number, the “non-coding” human genome is neglected when looking for genetic components of disease. WES platforms and pathogenic gene panels still do not cover even characterized lncRNA genes that are functionally involved in the pathophysiology of CVD. We suggest that the importance of lncRNAs in disease causation and progression be taken as seriously as that of pathogenic protein variants and mutations, and that this is maybe a new area of attention for clinical geneticists.
Keywords: cardiovascular disease (CVD); long non-coding RNA (lncRNA); whole exome sequencing (WES); whole genome sequencing (WGS); pathogenic gene variants cardiovascular disease (CVD); long non-coding RNA (lncRNA); whole exome sequencing (WES); whole genome sequencing (WGS); pathogenic gene variants
MDPI and ACS Style

Azodi, M.; Kamps, R.; Heymans, S.; Robinson, E.L. The Missing “lnc” between Genetics and Cardiac Disease. Non-Coding RNA 2020, 6, 3.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop